Macrolide antibiotics for cystic fibrosis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD002203.pub3PMID 22161368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.

  2020cited by this paper
• Macrolide antibiotics for cystic fibrosis.

  2012cited by this paper
• Maintenance Azithromycin Treatment in Pediatric Patients With Cystic Fibrosis: Long-Term Outcomes Related to Macrolide Resistance and Pulmonary Function

  2007cited by this paper
• Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis.

  2006cited by this paper
• Macrolide antibiotics for cystic fibrosis.

  2003cited by this paper
• Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis.

  2003cited by this paper
• Pathogenicity of microbes associated with cystic fibrosis.

  1999cited by this paper
• Anti-inflammatory activity of macrolides: a new therapeutic potential?

  1998cited by this paper
• The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro.

  1996cited by this paper
• Therapeutic possibilities for diffuse panbronchiolitis.

  1993cited by this paper
• Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

  1993cited by this paper

• Breastfeeding and early Bifidobacterium-driven microbial colonization shape the infant gut resistome

  2025cites this paper
• Macrolide antibiotics (including azithromycin) for cystic fibrosis.

  2024cites this paper
• Prevention of Inflammatory Disorders in the Preterm Neonate: An Update with a Special Focus on Bronchopulmonary Dysplasia

  2024cites this paper
• Seasonal Azithromycin Use in Paediatric Protracted Bacterial Bronchitis Does Not Promote Antimicrobial Resistance but Does Modulate the Nasopharyngeal Microbiome

  2023cites this paper
• Novel Immunomodulatory Therapies for Respiratory Pathologies

  2022cites this paper
• Local Delivery of Azithromycin Nanoformulation Attenuated Acute Lung Injury in Mice

  2022cites this paper
• Implementing the use of objective medication adherence data in routine clinical practice via the digital CFHealthHub platform: situation analysis and strategy development using the theoretical domains framework

  2021cites this paper
• Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation

  2020cites this paper
• Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies

  2020cites this paper
• Chronic lung disease in children and adolescents with HIV: a case–control study

  2020cites this paper
• Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study

  2019cites this paper
• Which patients with respiratory disease need long-term azithromycin?

  2017cites this paper
• Effects of Antibiotics on Gut Microbiota

  2016cites this paper
• Efficacy and adverse effects of drugs used to treat adult cystic fibrosis

  2015cites this paper
• [National consensus regarding azithromycin use in cystic fibrosis].

  2015cites this paper
• Azithromycin: mechanisms of action and their relevance for clinical applications.

  2014cites this paper
• Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.

  2013cites this paper
• Treatment of pulmonary exacerbations in cystic fibrosis

  2013cites this paper
• Preventing acute exacerbations and hospital admissions in COPD.

  2013cites this paper
• Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment*

  2013cites this paper
• Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion.

  2013cites this paper
• Interference of bacterial cell-to-cell communication: a new concept of antimicrobial chemotherapy breaks antibiotic resistance

  2013cites this paper
• Mitochondrial OXPHOS function is unaffected by chronic azithromycin treatment.

  2013cites this paper
• The Role of the Manipulation of the Gut Microbiota in Obesity

  2013cites this paper
• The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection

  2013cites this paper
• Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

  2013cites this paper
• Gut bacterial microbiota and obesity.

  2013cites this paper
• Pneumonies : actualités thérapeutiques et épidémiologiques

  2013cites this paper
• A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic.

  2013cites this paper
• Long-term macrolide treatment for chronic respiratory disease

  2012cites this paper
• Macrolides for macrophages in chronic obstructive pulmonary disease

  2012cites this paper
• Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

  2012cites this paper
• Long-term combination treatment of azithromycin with other macrolides: a new era.

  2012cites this paper
• [The safety of macrolide antibiotics: critical analysis].

  2012cites this paper
• Consider adding this drug to fight COPD that's severe.

  2012cites this paper
• Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi-centre randomized controlled trial

  2012cites this paper
• Macrolide antibiotics for cystic fibrosis.

  2012cites this paper
• Anti-inflammatory effects of macrolides in childhood lung diseases.

  2012cites this paper
• Treatment with anti‐inflammatory drugs in community‐acquired pneumonia

  2012cites this paper
• Pathogen- and Host-Directed Anti-Inflammatory Activities of Macrolide Antibiotics

  2012cites this paper
• Macrolide antibiotics for cystic fibrosis.

  2012cites this paper